» Articles » PMID: 32143514

The G Protein-Coupled Estrogen Receptor (GPER) Expression Correlates with Pro-Metastatic Pathways in ER-Negative Breast Cancer: A Bioinformatics Analysis

Overview
Journal Cells
Publisher MDPI
Date 2020 Mar 8
PMID 32143514
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

The G protein-coupled estrogen receptor (GPER, formerly known as GPR30) is a seven-transmembrane receptor that mediates estrogen signals in both normal and malignant cells. In particular, GPER has been involved in the activation of diverse signaling pathways toward transcriptional and biological responses that characterize the progression of breast cancer (BC). In this context, a correlation between GPER expression and worse clinical-pathological features of BC has been suggested, although controversial data have also been reported. In order to better assess the biological significance of GPER in the aggressive estrogen receptor (ER)-negative BC, we performed a bioinformatics analysis using the information provided by The Invasive Breast Cancer Cohort of The Cancer Genome Atlas (TCGA) project and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) datasets. Gene expression correlation and the statistical analysis were carried out with R studio base functions and the tidyverse package. Pathway enrichment analysis was evaluated with Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway on the Database for Annotation, Visualization and Integrated Discovery (DAVID) website, whereas gene set enrichment analysis (GSEA) was performed with the R package phenoTest. The survival analysis was determined with the R package survivALL. Analyzing the expression data of more than 2500 primary BC, we ascertained that GPER levels are associated with pro-migratory and metastatic genes belonging to cell adhesion molecules (CAMs), extracellular matrix (ECM)-receptor interaction, and focal adhesion (FA) signaling pathways. Thereafter, evaluating the disease-free interval (DFI) in ER-negative BC patients, we found that the subjects expressing high GPER levels exhibited a shorter DFI in respect to those exhibiting low GPER levels. Overall, our results may pave the way to further dissect the network triggered by GPER in the breast malignancies lacking ER toward a better assessment of its prognostic significance and the action elicited in mediating the aggressive features of the aforementioned BC subtype.

Citing Articles

The Use of Biologics for Targeting GPCRs in Metastatic Cancers.

McBrien C, OConnell D BioTech (Basel). 2025; 14(1).

PMID: 39982274 PMC: 11843943. DOI: 10.3390/biotech14010007.


Let-7b, miR-29b, and miR-125b as Potential Biomarkers for Differentiating Canine Mammary Carcinoma Histological Types.

Ferreira T, Dias F, Alves A, Gama A, Mano J, Oliveira P Animals (Basel). 2025; 15(1.

PMID: 39794962 PMC: 11718878. DOI: 10.3390/ani15010020.


G protein-coupled estrogen receptor 1 and collagen XVII endodomain expression in human cutaneous melanomas: can they serve as prognostic factors?.

Cakir U, Balogh P, Ferenczik A, Brodszky V, Krenacs T, Karpati S Pathol Oncol Res. 2024; 30:1611809.

PMID: 39252786 PMC: 11381273. DOI: 10.3389/pore.2024.1611809.


The G Protein Estrogen Receptor (GPER) is involved in the resistance to the CDK4/6 inhibitor palbociclib in breast cancer.

Talia M, Cirillo F, Scordamaglia D, Di Dio M, Zicarelli A, De Rosis S J Exp Clin Cancer Res. 2024; 43(1):171.

PMID: 38886784 PMC: 11184778. DOI: 10.1186/s13046-024-03096-7.


Estetrol/GPER/SERPINB2 transduction signaling inhibits the motility of triple-negative breast cancer cells.

Cirillo F, Spinelli A, Talia M, Scordamaglia D, Santolla M, Grande F J Transl Med. 2024; 22(1):450.

PMID: 38741146 PMC: 11089683. DOI: 10.1186/s12967-024-05269-6.


References
1.
Deng Q, Jiang G, Wu Y, Li J, Liang W, Chen L . GPER/Hippo-YAP signal is involved in Bisphenol S induced migration of triple negative breast cancer (TNBC) cells. J Hazard Mater. 2018; 355:1-9. DOI: 10.1016/j.jhazmat.2018.05.013. View

2.
Zhu Y, Wan F, Shen Y, Wang H, Zhang G, Ye D . Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth. Oncotarget. 2015; 6(16):14488-96. PMC: 4546481. DOI: 10.18632/oncotarget.3697. View

3.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

4.
Hao S, Yang Y, Liu Y, Yang S, Wang G, Xiao J . JAM-C promotes lymphangiogenesis and nodal metastasis in non-small cell lung cancer. Tumour Biol. 2014; 35(6):5675-87. DOI: 10.1007/s13277-014-1751-1. View

5.
Stutchbury B, Atherton P, Tsang R, Wang D, Ballestrem C . Distinct focal adhesion protein modules control different aspects of mechanotransduction. J Cell Sci. 2017; 130(9):1612-1624. PMC: 5450230. DOI: 10.1242/jcs.195362. View